| Your Current Location : Fund Card : Portfolio Classification |
 |
|
|
| |
| Quant Healthcare Fund (G) Direct |
| [Equity: Sectoral] |
|
| |
|
|
| Instruments Breakdown |
| Instruments |
Composition |
| Current Asset |
0.01 |
| Equity |
95.20 |
| Treasury Bill |
6.85 |
| Trep |
-2.06 |
|
| |
| Concentration Analysis |
| Top 5 Holdings |
59.73% |
| Top 10 Holdings |
97.43% |
| Top 25 Holdings |
123.78% |
|
|
|
| |
| Sector Analysis |
| Sector/Ratings |
Net Asset(%) |
| Pharma & Biotech |
39.83 |
| Derivatives |
24.18 |
| Healthcare |
10.99 |
| Telecom |
10.76 |
| Food Beverage & Tobacco |
9.44 |
| SOV |
6.85 |
| Cash |
-2.05 |
|
|
|
|
|
| Portfolio Metrics |
|
| PB Ratio |
4.78 |
| PE Ratio |
44.45 |
|
| |
| Top 25 Holdings |
|
|
| Holdings |
Net Asset(%) |
| TREPS 01-Jul-2026 DEPO 10 |
21.73 |
| HFCL |
10.76 |
| EQ -ZYDUS WELLNESS LTD. |
9.44 |
| Aster DM Healthcare Limited |
8.96 |
| Concord Biotech Limited |
8.84 |
| Glenmark Pharmaceuticals Ltd |
8.70 |
| SMS Pharmaceuticals Limited |
8.15 |
| Alivus Life Sciences |
7.28 |
| Max Healthcare Institute Limited |
5.80 |
| Divis Laboratories Limited |
5.74 |
| Pfizer Limited |
5.44 |
| Aurobindo Pharma Limited |
5.22 |
| Aurobindo Pharma Limited |
3.94 |
| Strides Pharma Science Limited |
2.86 |
| GLAXO SMITHKLINE PHARMA |
2.04 |
| Max Healthcare Institute Limited |
2.03 |
| 91 Days Treasury Bill 16-Jul-2026 |
0.77 |
| 91 Days Treasury Bill 17-Sep-2026 |
0.76 |
| 91 Days Treasury Bill 10-Sep-2026 |
0.76 |
| 91 Days Treasury Bill 03-Sep-2026 |
0.76 |
| 91 Days Treasury Bill 28-Aug-2026 |
0.76 |
| 91 Days Treasury Bill 20-Aug-2026 |
0.76 |
| 91 Days Treasury Bill 13-Aug-2026 |
0.76 |
| 91 Days Treasury Bill 06-Aug-2026 |
0.76 |
| 91 Days Treasury Bill 23-Jul-2026 |
0.76 |
|
|
|
| |
|
| |
| Sector Analysis Graphical Mode |
|
| |
|
|
| |
|
 |
| |
|
|
|
